This section provides various financial ratios derived from the company's financial statements to help assess its performance and financial health. Below are Current Ratio, Quick Ratio, Cash Ratio, Debt to Asset Ratio, Return on Equity, P/E Ratio for SYRE as of 2026-03-31.
| Financial Ratios | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| P/E Ratio | - | -0.058 | -0.075 | -1.026 |
| Return on Equity | -10.287 | -19.286 | -2.457 | -0.072 |
| Debt to Asset Ratio | 12.192 | 8.041 | 9.81 | 15.415 |
| Cash Ratio | 114.118 | 146.07 | 140.245 | 98.314 |
| Quick Ratio | 897.059 | 1,325.349 | 1,090.47 | 648.734 |
| Current Ratio | 897.059 | 1,325.349 | 1,090.47 | 648.734 |
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)